To Bridge or Not to Bridge:Modelling Periprocedural Anticoagulation Management by van der Pol, Simon et al.
  
 University of Groningen
To Bridge or Not to Bridge
van der Pol, Simon; Jacobs, Maartje; Meijer, Karina; Piersma-Wichers, Margriet G.; Tieleman,
RG; Postma, Maarten; van Hulst, Marinus
DOI:
10.1177/0272989X18793413
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van der Pol, S., Jacobs, M., Meijer, K., Piersma-Wichers, M. G., Tieleman, RG., Postma, M., & van Hulst,
M. (2018). To Bridge or Not to Bridge: Modelling Periprocedural Anticoagulation Management. E417.
Poster session presented at 17th Biennial European Meeting of the Society for Medical Decision Making,
Leiden, Netherlands. https://doi.org/10.1177/0272989X18793413
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
Bridging anticoagulation in atrial fibrillation patients who 
need to interrupt vitamin K antagonists for procedures is a 
clinical dilemma. Currently, guidelines recommend 
clinicians to take the stroke and bleeding risk into 
consideration, but no clear patient-specific thresholds are 
advised. 
Using a Markov model,  we compared two clinical 
strategies:  administering vs. withholding periprocedural 
bridging therapy in atrial fibrillation patients, using clinical 
stroke (CHA2DS2-VASc) and bleeding (HAS-BLED) 
scores. The effect of INR management was investigated by 
modelling different post-procedural periods to reach 
therapeutic INR.
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Background
Methods
A probabilistic Markov model was 
developed to simulate both a bridge and 
a non-bridge cohort of AF patients 
periprocedurally (5 days before and 30 
days after the procedure). Quality-
adjusted life expectancy after the 
procedure, was the main outcome 
considered. The base case considered 
women 75-80 years old.
Strokes were modelled using CHA2DS2-
VASc scores, incorporating the stroke 
preventive effects of warfarin and the 
LMWH using the INR trajectories. Long-
term disabilities were taken into account 
using utility values. An increased post-
operative stroke risk was applied, as 
compared to the population risks, using 
data published by Kaatz et al.
Bleedings were simulated using  the 
rates as reported in the BRIDGE trial, as 
an average for many procedures. Two 
groups were included: low-risk (HAS-
BLED 0-2) and high-risk patients (HAS-
BLED ≥ 3). For high-risk patients, an 
additional bleeding risk was applied, as 
described in literature by Omran et al.
Results
The base case analysis shows that 
bridging anticoagulation increases the 
bleeding rate, but reduces the stroke 
rate. Bridging may be beneficial for the 
quality-adjusted life expectancy in 
patients with a CHA2DS2-VASc scores of 
6 or higher and HAS-BLED scores of 0 to 
2. Bridging is less likely to be beneficial if 
the life expectancy is shorter. For 
expected shorter periods to reach 
therapeutic INR, bridging therapy is less 
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For patients at high risk of stroke and low risk of 
bleeding (CHA2DS2-VASc ≥ 6 and HAS-BLED ≤ 2), 
bridging anticoagulation may result in additional 
quality-adjusted life years. For patients at high risk 
of bleeding or at a low risk of stroke, bridging 
anticoagulation is unlikely to be beneficial . In 
practice, few patients are expected to benefit from 
bridging. INR management is an important factor to 
consider periprocedurally when making the 
decision whether to bridge.
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